Several landmark randomized‐controlled trials (RCT)s have demonstrated the efficacy of sodium‐glucose co‐transport 2 (SGLT2) inhibitors in reducing all‐cause mortality, cardiovascular (CV) mortality and rates of heart failure (HF) hospitalizations in patients with HF.1, 2, 3, 4, 5. This evidence concerns the gene SLC5A2 and heart failure.